Cited 0 time in
Polymorphisms in drug transporter genes (ABCB1, SLCO1B1 and ABCC2) and hepatitis induced by antituberculosis drugs
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Kim, Sang-Hoon | - |
| dc.contributor.author | Kim, Sang-Heon | - |
| dc.contributor.author | Lee, Jae-Hyung | - |
| dc.contributor.author | Lee, Byoung-Hoon | - |
| dc.contributor.author | Kim, Youn-Seup | - |
| dc.contributor.author | Park, Jae-Seuk | - |
| dc.contributor.author | Jee, Young-Koo | - |
| dc.date.accessioned | 2022-07-16T17:07:08Z | - |
| dc.date.available | 2022-07-16T17:07:08Z | - |
| dc.date.issued | 2012-01 | - |
| dc.identifier.issn | 1472-9792 | - |
| dc.identifier.issn | 1873-281X | - |
| dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/166535 | - |
| dc.description.abstract | Unusual drug accumulation is a common mechanism underlying serious drug-induced liver injury. Polymorphisms in three drug transporter genes (ABCB1, SLCO1B1 and ABCC2) may be risk markers for hepatitis induced by the unusual accumulation of anti-tuberculosis drugs (ATDs). We therefore investigated whether polymorphisms and haplotypes of these genes are associated with ATD-induced hepatitis by comparing the frequencies and distributions of single nucleotide polymorphisms and haplotypes of these three drug transporter genes among 67 patients with ATD-induced hepatitis and 159 patients tolerant to ATDs using a multivariate logistic regression analysis. We found that the frequencies of polymorphisms and haplotypes of ABCB1, SLCO1B1 and ABCC2 were similar in patients with ATD-induced hepatitis and ATD-tolerant controls. The present results suggest that these drug transporters do not play important roles in the pathogenesis of ATD-induced hepatitis in Korean patients. | - |
| dc.format.extent | 5 | - |
| dc.language | 영어 | - |
| dc.language.iso | ENG | - |
| dc.publisher | Churchill Livingstone | - |
| dc.title | Polymorphisms in drug transporter genes (ABCB1, SLCO1B1 and ABCC2) and hepatitis induced by antituberculosis drugs | - |
| dc.type | Article | - |
| dc.publisher.location | 영국 | - |
| dc.identifier.doi | 10.1016/j.tube.2011.09.007 | - |
| dc.identifier.scopusid | 2-s2.0-84856454431 | - |
| dc.identifier.wosid | 000299957400014 | - |
| dc.identifier.bibliographicCitation | Tuberculosis, v.92, no.1, pp 100 - 104 | - |
| dc.citation.title | Tuberculosis | - |
| dc.citation.volume | 92 | - |
| dc.citation.number | 1 | - |
| dc.citation.startPage | 100 | - |
| dc.citation.endPage | 104 | - |
| dc.type.docType | Article | - |
| dc.description.isOpenAccess | N | - |
| dc.description.journalRegisteredClass | scie | - |
| dc.description.journalRegisteredClass | scopus | - |
| dc.relation.journalResearchArea | Immunology | - |
| dc.relation.journalResearchArea | Microbiology | - |
| dc.relation.journalResearchArea | Respiratory System | - |
| dc.relation.journalWebOfScienceCategory | Immunology | - |
| dc.relation.journalWebOfScienceCategory | Microbiology | - |
| dc.relation.journalWebOfScienceCategory | Respiratory System | - |
| dc.subject.keywordPlus | INDUCED HEPATOTOXICITY | - |
| dc.subject.keywordPlus | METABOLIZING-ENZYMES | - |
| dc.subject.keywordPlus | SUSCEPTIBILITY | - |
| dc.subject.keywordPlus | RISK | - |
| dc.subject.keywordPlus | MUTATIONS | - |
| dc.subject.keywordPlus | HAPLOTYPE | - |
| dc.subject.keywordPlus | GENOTYPE | - |
| dc.subject.keywordAuthor | Drug transporter | - |
| dc.subject.keywordAuthor | Antituberculosis drug | - |
| dc.subject.keywordAuthor | Hepatitis | - |
| dc.identifier.url | https://www.sciencedirect.com/science/article/pii/S1472979211001673?via%3Dihub | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1366
COPYRIGHT © 2024 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
